Misdiagnosed follicular adenoma with 11 year postoperative liver and lung metastases a case report and literature review Authors: Kai-Li Yang, Heng-Tong Han, Shou-Hua Li, Xiao-Xiao Li, Ze Yang, Li-Bin Ma, Yong-Xun Zhao Published: 2025 ABSTRACT BackgroundAs the second most common thyroid cancer, the follicular form has a good prognosis, but it is easily confused with follicular adenoma pre-operatively, which often leads to misdiagnosis, delayed treatment, and an increased risk of hematogenous metastasis. The optimization of diagnostic and treatment strategies is crucial for increasing the early diagnosis rate and improving the prognosis.Case presentationA 73-year-old male was misdiagnosed as "follicular adenoma" 11 years previously and the left thyroid adenoma was resected. He was admitted with a confirmed diagnosis of follicular thyroid cancer and multiple metastases to the liver and lungs. A total resection of the left residual thyroid and the right thyroid and isthmus was performed, combined with bilateral central lymph node dissection, and post-operatively, two 131I-NaI 100 mCi treatments for the metastatic foci in the liver and lungs were administered, as well as regularly receiving oral levothyroxine replacement therapy. The one-year follow-up showed no recurrence of the primary foci and a significant reduction in metastatic foci, confirming the effectiveness of the comprehensive treatment program.ConclusionPre-surgery, follicular thyroid carcinoma is easily confused with follicular adenoma and nodular goiter with non-invasive encapsulated follicular tumors with papillary carcinoma nuclei, and it requires standardized treatment and detection of metastatic foci. Surgery combined with radioiodine is the mainstay of treatment and it is supplemented with levothyroxine replacement therapy. Targeted drugs are available for patients, refractory to radiotherapy. Long-term follow-up is essential to improve the prognosis. Introduction Thyroid tumors are the most common endocrine tumors [1]. According to the WHO International Agency for Research on Cancer GLOBOCAN 2022 database, the incidence of thyroid cancer is the seventh most common globally [2], and the increased reported incidence is associated with exposure to risk factors and improved diagnostic techniques [3]. Follicular thyroid cancer (FTC) is the second most common type of thyroid cancer [4], after differentiated thyroid cancer (DTC), with a long-term survival rate of more than 90% following standardized treatment [5]. However, 3% to 20% of patients with FTC develop distant metastases (DM) during treatment or follow up [6], which is the leading cause of FTC-related death [7]. The most common sites of DM in FTC are the lungs and bones [8], and liver metastases tend to be multiple [7]. Surgery is the mainstay of treatment for FTC and is often combined with radioiodine (RAI) to remove residual tissue and metastases [9, 10]. For patients, refractory to radioactive iodine, tyrosine kinase inhibitors (TKIs) and targeted therapies are viable options. The diagnosis of FTC is particularly critical, with serum thyroid-stimulating hormone (TSH) and thyroglobulin (Tg) levels, thyroid ultrasonography, and fine-needle aspiration (FNA) as the main ancillary investigations. FNA is the main auxiliary test, and intra-operative frozen section examination and post-operative histopathological examination can further clarify the diagnosis; thus, guiding standardized treatment and avoiding residual thyroid cancer and DM caused by misdiagnosis. Nevertheless, the differential diagnosis between FTC and benign or borderline follicular tumors such as follicular thyroid adenoma (FA) and nodular goiter with papillary nucleus features (NIFTP) remains a clinical challenge and hotspot, as all three are predominantly follicular in structure with overlapping clinical presentations, ultrasonography features, and histopathological features [11, 12]. Pre-operative differentiation of FTC from FA and NIFTP is extremely challenging, and misdiagnosis affects decision-making by medical practitioners, which in turn affects patient outcomes and prognosis. Immunohistochemistry, molecular markers, and liquid biopsy have shown great potential for the diagnosis of FTC. Herein, we report the case of an older male who was initially diagnosed with FA, had a left-sided thyroid adenoma resected, which progressed to FTC with liver and lung metastases 11 years later. We summarize the current status of the diagnosis and treatment of FTC in relation to the literature and provide insights into the future diagnosis and treatment of FTC by integrating imaging methods, FNA, molecular diagnostic techniques, liquid biopsy, and post-operative histopathology and by integrating immunohistochemistry, molecular markers, and liquid biopsy. The integration of imaging methods, FNA, molecular diagnostic techniques, liquid biopsy, post-operative histopathology, and immunohistochemistry to form a comprehensive diagnostic model improves diagnostic accuracy and efficiency and realizes the early and accurate diagnosis of FTC and its accurate differentiation from FA and NIFTP. It is hoped that this can provide reference for future medical practitioners to diagnose and treat patients with FTC and DM. Case presentation A 73-year-old male with a left-sided thyroid adenoma sought medical attention 11 years after left-sided thyroid adenomectomy and three years after the discovery of a neck mass. The patient was treated for the left-sided thyroid tumor 11 years previously in an outside hospital, and pre-operative and intra-operative tests suggested FA (specific results were not provided). Post-operative histopathology supported the diagnosis of FA (self-reported by the patient and his family, and the histopathology report was not provided), and the patient underwent adenomectomy of the left side of the thyroid in accordance with the guidelines for the treatment of FA. He was not prescribed levothyroxine (LT4) substitution therapy post-surgery, and did not have regular thyroid function tests or ultrasonography of the neck. There was no obvious cause for the reappearance of the neck mass, no skin redness, swelling, ulceration, hoarseness, choking or coughing, chest tightness, emotional provocation, trembling hands, or profuse sweating, and ultrasonography of the neck in other hospital showed that Low echo mass adjacent to residual thyroid gland on the left side, approximately 1.7 cm×1.4 cm×1.2 cm in size, with clear boundaries and a regular morphology, and a blood flow signal was visible in the interior and the surrounding area. There were many hypoechoic subcutaneous masses adjacent to the sternum with clear boundaries, the bilateral lymph nodes were clear, the bilateral lymph nodes were not abnormal, and no further diagnosis or treatment was performed. The patient had no underlying diseases, such as diabetes mellitus or hypertension, no radiation exposure, or related family history. Routine blood and biochemical tests were normal. Pre-operative thyroid function tests showed total triiodothyronine (TT3), 1.83 ng/ml; free triiodothyronine (FT3), 5.65 pg/ml; free thyroxine (FT4), 1.63 ng/dl; TSH, < 0.005 mIU/L; Tg, > 488.00 ng/ml; and thyroglobulin antibody (TgAb ), < 0.9IU/ml (Fig. 7). Ultrasonography and computed tomography (CT) are valuable tools for differentiating between benign and malignant thyroid tumors [13]. Color ultrasonography of the thyroid gland and abdomen showed several moderately echogenic areas in the left lobe of the thyroid gland, with clear borders and regular morphology, the larger one approximately 1.7cmX1.4 cm in size, and there were no obvious abnormalities in the cervical lymph nodes. The right lobe of the liver showed an inhomogeneous moderately hypoechoic area of approximately 9.5cmX7.7 cm in size and clear borders, with a regular morphology and a blood flow signal inside and at the edges of the lobe (Fig. 1). Enhanced electron computed tomography (CT) of the neck, chest and abdomen showed a rounded hypoechoic nodule in the left lobe of the thyroid gland, approximately 1.6cmX1.6 cm in size. There were multiple abnormally reinforced nodules in both lungs, with the largest foci located in the upper lobes of both lungs, and the density change in the enhancement scans was not obvious; therefore, metastasis of thyroid cancer to the lung was considered There was abnormal reinforced occupancy of the liver in the S4 segment, approximately 7.7cmX8.9 cm in size, and the enhancement was persistent (Fig. 2). A whole-body bone scan showed abnormal bone metabolism in the T9-11 and L4-5 vertebrae, and no bone metastases were observed (Fig. 3). Tissue sections of the thyroid gland prepared 11 years previously at the outside hospital were retrieved, which showed follicular hyperplasia with a thick-walled fibrous envelope, some non-penetrating follicles adjacent to the envelope, and enlarged and mildly irregular nuclei, but no papillary carcinoma nuclear grooves or overlapping. Immunohistochemistry showed Ki-67 (focal 15%), CK19 (focal+), TPO (focal+), and CD56 (-), which met the 2017 WHO diagnostic criteria for NIFTP (absence of invasive growth and nuclear features confined to follicles) [14]. Liver metastasis of FTC (follicular arrangement and immunohistochemistry TTF-1, Tg, and Pax-8 positive and Ki-67 5%) was diagnosed by hepatic puncture biopsy on the current admission (Fig. 4). After a multi-disciplinary team discussion of the clinical symptoms, laboratory tests, imaging, and histopathological findings, a diagnosis of FTC with liver metastasis and lung metastasis was clear. According to the latest guidelines for the treatment of thyroid diseases, the indications for surgery were clear [10]. After evaluating the patient indexes, a left residual thyroid plus right thyroid and isthmus resection combined with bilateral central lymph node dissection was selected. LT4 replacement therapy (TSH < 0.1mIU/L), and 131I-NaI 100mCi foci clearing treatment were administered at two months and five months, post-operatively, respectively. Results and follow-up Routine post-operative histopathological examination revealed follicular, beam-like and solid arrangement of tumor cells with rounded and uniform nuclei and interstitial edema with vascular invasion and a satellite nodular shape. Immunohistochemistry revealed CK19 (1+), Ki-67 (15%), TTF-1 (2+), and CD31 (vascular+) (Fig. 5), which is consistent with the histopathological features of FTC [15]. The main difference between FTC and FA and NIFTP is the presence of penetrating peritumoral infiltration or vascular invasion [16]. No metastatic cancer was found in the central lymph nodes. Thyroid function testing and neck ultrasonography were regularly performed one year post-surgery, and the dosage of LT4 was continually adjusted based on the results of the thyroid function testing to ensure that the serum TSH level was maintained in the appropriate range (TSH < 0.1 mIU/L). The patient was administered the first 131I-NaI100mCi treatment two months post-operatively, with whole-body imaging and tomographic fusion. There was functional thyroid tissue residue in the bed area of the left lobe of the thyroid gland (Fig. 6A1), increased uptake of RAI in the lower lobes of both lungs in the nodules, which were considered to be metastases of thyroid cancer (Fig. 6B1), and foci of abnormal uptake of RAI were observed in the S4 segment of the liver, and combined with the histopathology, FTC with liver metastasis was considered (Fig. 6C1). Systemic imaging during the second 131I-NaI100mCi treatment six months post-operatively showed the foci of RAI concentration in the bed area of the left lobe of the thyroid gland were not present (Fig. 6A2), the number of microscopic nodules in both lungs was reduced, and there was no obvious uptake of RAI (Fig. 6B2), the foci of metastases in the liver were slightly reduced compared to the previous treatment, and the radioactivity uptake was reduced (Fig. 6C2). One year post-operatively, the abdominal CT images were reviewed and the metastasis in the S4 segment of the liver was reduced, and the density of the tumor was reduced, accompanied by liquefaction of the tumor (Fig. 2C). Thyroid function testing one year post-operatively showed T3, 2.03 noml/L; FT3, 6.7 pmol/L; FT4, 22.1 pmol/L; and TSH, 0.008 mIU/L (Fig. 7). The treatment was effective. Fig. 1Pre-operative thyroid and abdominal color ultrasonography: A thyroid ultrasonography image: the left lobe of the thyroid gland has several moderately echogenic areas, the larger of which is 17 mm×14 mm. B abdominal ultrasound: the right lobe of the liver is 95 mm×77 mm with uneven medium-low echogenicity; the bile ducts of the liver are displaced by the pressure; and the blood flow signals in the inner portion of the liver and the edges Pre-operative thyroid and abdominal color ultrasonography: A thyroid ultrasonography image: the left lobe of the thyroid gland has several moderately echogenic areas, the larger of which is 17 mm×14 mm. B abdominal ultrasound: the right lobe of the liver is 95 mm×77 mm with uneven medium-low echogenicity; the bile ducts of the liver are displaced by the pressure; and the blood flow signals in the inner portion of the liver and the edges Fig. 2Pre-operative and post-operative enhancement computed tomography (CT) of the neck, chest, and abdomen: A pre-operative enhancement CT of the neck shows the left lobe of the thyroid gland with rounded hypoechoic nodules, 1.6 cm×1.6 cm in size; B pre-operative enhancement CT of the chest shows bilateral lungs with multiple abnormal nodules with the largest foci in the upper lobes; C pre-operative enhancement CT of the abdomen shows an abnormally strengthened mass in the S4 segment of the liver, 7.7 cm×8.9 cm in size with continuous sustained enhancement; D 131I-NaI100mCi enhancement CT of the abdomen after six months of treatment shows that the metastatic tumor of S4 segment of the liver is reduced in size and density, with a CT value of 16Hu (considering the liquefaction of the tumor) Pre-operative and post-operative enhancement computed tomography (CT) of the neck, chest, and abdomen: A pre-operative enhancement CT of the neck shows the left lobe of the thyroid gland with rounded hypoechoic nodules, 1.6 cm×1.6 cm in size; B pre-operative enhancement CT of the chest shows bilateral lungs with multiple abnormal nodules with the largest foci in the upper lobes; C pre-operative enhancement CT of the abdomen shows an abnormally strengthened mass in the S4 segment of the liver, 7.7 cm×8.9 cm in size with continuous sustained enhancement; D 131I-NaI100mCi enhancement CT of the abdomen after six months of treatment shows that the metastatic tumor of S4 segment of the liver is reduced in size and density, with a CT value of 16Hu (considering the liquefaction of the tumor) Fig. 3Pre-operative whole-body nuclear bone imaging shows localized abnormalities of bone metabolism in the T9 to T11 vertebrae and the L4 and L5 vertebrae, which are considered to be benign bone lesions Pre-operative whole-body nuclear bone imaging shows localized abnormalities of bone metabolism in the T9 to T11 vertebrae and the L4 and L5 vertebrae, which are considered to be benign bone lesions Fig. 4Histopathology of the pre-operative ultrasonography-assisted percutaneous hepatic aspiration biopsy. A, B Hematoxylin and eosin staining shows hepatic metastasis of follicular thyroid carcinoma Histopathology of the pre-operative ultrasonography-assisted percutaneous hepatic aspiration biopsy. A, B Hematoxylin and eosin staining shows hepatic metastasis of follicular thyroid carcinoma Fig. 5Post-operative histopathology: A, B hematoxylin and eosin staining shows follicular thyroid carcinoma Post-operative histopathology: A, B hematoxylin and eosin staining shows follicular thyroid carcinoma Fig. 6Whole-body imaging during the first 131I-NaI100mCi treatment two months post-operatively: A1: there is functional thyroid tissue in the left lobe bed area of the thyroid gland; B1: there is increased radioactive iodine uptake in the lower lobe nodules of the two lungs; C1: there are obvious foci of abnormal radioactive uptake in the S4 segment of the liver. Whole-body imaging during the second 131I-NaI100mCi treatment at six months post-operatively shows that, compared with the first 131I-NaI100mCi treatment: A2: the radioactive iodine-concentrating foci in the bed area of the left lobe of the thyroid gland are not present; B2: there is a decrease in the number of microscopic nodules in both lungs, with no obvious uptake of radioactive iodine; and C2: there is a minimal decrease in the number of metastatic foci in the liver, with a decrease in the uptake of radioactive iodine Whole-body imaging during the first 131I-NaI100mCi treatment two months post-operatively: A1: there is functional thyroid tissue in the left lobe bed area of the thyroid gland; B1: there is increased radioactive iodine uptake in the lower lobe nodules of the two lungs; C1: there are obvious foci of abnormal radioactive uptake in the S4 segment of the liver. Whole-body imaging during the second 131I-NaI100mCi treatment at six months post-operatively shows that, compared with the first 131I-NaI100mCi treatment: A2: the radioactive iodine-concentrating foci in the bed area of the left lobe of the thyroid gland are not present; B2: there is a decrease in the number of microscopic nodules in both lungs, with no obvious uptake of radioactive iodine; and C2: there is a minimal decrease in the number of metastatic foci in the liver, with a decrease in the uptake of radioactive iodine Fig. 7Line graphs showing thyroid function, pre-operatively (A), post-operatively (B), 11 months post-operatively (C), and one year post-operatively (D). TSH: thyroid-stimulating hormone; TT3: total triiodothyronine; FT3: free triiodothyronine; FT4: free thyroxine Line graphs showing thyroid function, pre-operatively (A), post-operatively (B), 11 months post-operatively (C), and one year post-operatively (D). TSH: thyroid-stimulating hormone; TT3: total triiodothyronine; FT3: free triiodothyronine; FT4: free thyroxine Discussion FTC has a follicular structure without the typical nuclear features of papillary thyroid carcinoma (PTC) [17] and there is a peri-tumor tumor with peri-tumor and/or vascular infiltration that has relatively rare local invasion compared to PTC. However, FTC has a higher rate of distant metastases, is usually more aggressive than PTC, and the prognosis is poorer than that of classical PTC [18]. FTC usually metastasizes predominantly hematogenously, rather than via the lymphatics [10]. In the current case, because there was hematogenous metastasis to the liver and lungs the diagnosis of FTC was clear, although there was no metastasis to the cervical lymph nodes, which is consistent with the metastatic pathway of FTC. The prognosis of FTC is usually favorable, with a 10-year survival rate of 77.0% and a 20-year survival rate of 33.7% [19]. The overall survival can be improved through standardized diagnosis and treatment. The differentiation of FTC from FA and NIFTP has always been a key and difficult task in the clinic. FTC, as a potentially aggressive thyroid malignancy, is often misdiagnosed due to its morphological similarity to FA and NIFTP, which delays optimal treatment. FTC, FA, and NIFTP are composed of differentiated follicular cells [20], with overlapping cellular structures, which retain the basic structure of the follicular epithelial cells of the thyroid. As the basic structure of thyroid follicular epithelial cells is retained it is difficult to distinguish them based on cell morphology alone [21]. However, it was possible to distinguish between the three forms using post-operative histopathological examination, combined with immunohistochemistry. FTC has peri-tumor or vascular invasion and obvious nuclear heterogeneity [22], whereas FA has an intact peri-tumor membrane, no vascular invasion, and no nuclear heterogeneity [23] and NIFTP has an intact peri-tumor membrane, no invasion, and the nuclei have a full range of PTC-like nuclei (nuclear grooves and overlapping nuclei) without a papillary structure [22]. The immunohistochemistry was suggestive of the diagnosis of FTC as CD31 is a specific marker for vascular endothelial cells. If the tumor cells invade the vessel wall or there is intravascular cancer thrombus, this can directly prove vascular infiltration, which is one of the key diagnostic criteria to distinguish FTC from FA and NIFTP [24]. The Ki-67 marker reflects proliferative activity, and the positivity rate of Ki-67 in FTC is usually higher than that in FA, although NIFTP has no papillary structure, and the positivity rate of Ki-67 in NIFTP is higher than that in FA. Although the Ki-67 index of NIFTP may also be minimally elevated, the Ki67 index of 15% in this patient suggests that the tumor cells are more actively proliferating, which supports the diagnosis of malignancy [25]. CK19 is often focally positive in FTC and may be strongly positive in some patients, whereas it is mostly negative or weakly expressed in FA; a positive expression suggests that the tumor cells have lower differentiation and higher malignant potential [26]. Currently, the pre-operative differential diagnosis of FTC, FA, and NIFTP is mainly performed using a combination of imaging and histopathology [27, 28], serum TSH level, ultrasonography, and FNA. Serum TSH plays a crucial role in the growth and progression of FTC as it promotes proliferation of thyroid cells by binding to TSH receptors on the surface of follicular cells and activating the cAMP/PKA pathway. Stimulation of TSH may accelerate tumor growth, and several studies have demonstrated a positive correlation between an elevated pre-operative TSH level and the risk of malignancy [29]. The serum Tg level is a reliable marker for detecting recurrent and persistent disease in patients with FTC during follow-up [30]. Thyroid function parameters, such as TSH, FT3, FT4, and Tg were regularly tested in this patient during the post-operative follow-up period as important indicators of efficacy and monitoring of recurrence to guide standardized treatment. Thyroid ultrasonography is the imaging tool of choice for evaluating FTC and its malignant features, and although related to the degree of risk of thyroid nodules [31–33], none of these features have been shown to be specific for FTC. FNA and cytology are the core tools for pre-operative evaluation of FTC, and they are very important differential diagnostic tools for FTC. In patients where ultrasonography suggests that the nodules have malignant features and during the course of regular follow-up, it is found that the nodule has increased significantly in size and grown faster in a short period of time, FNA should be performed in a timely manner to exclude the possibility of a malignant lesion [34]. However, FNA only provides cell morphology, which can exclude other types of thyroid cancer, such as PTC, but it cannot provide morphology of the overall structure of the tumor (e.g., the integrity of the peripheral membrane or vascular invasion). Thus, it is difficult to differentiate between benign and malignant tumors from FNA samples. Coarse needle aspiration is more suitable for immunohistochemistry than FNA because a tissue sample is obtained, but the gold standard of “peritoneal/vascular invasion” cannot be observed, and the final diagnosis relies on complete histopathological examination of surgically resected specimens. In recent years, molecular biology testing has significantly improved the accuracy of pre-operative differentiation of FTC, FA, and NIFTP by detecting RAS, TP53, TERT promoter mutations, and PAX8/PPARγ rearrangements. RAS mutations are the most common oncogenic drivers in FTC [35] and correlate with poor overall survival and distant metastases [36, 37]. Although FTC, FA, or NIFTP may be present, FNA combined with detection of RAS mutations significantly improves the accuracy of the pre-operative diagnosis of FTC. It has been shown that the sensitivity of the FNA-assisted diagnosis of malignancy increases from 60% with cytology alone to 90% when cytology-based molecular testing is combined [38, 39]. This has significant value in encapsulated follicular tumors that are morphologically difficult to differentiate as it can be accomplished pre-operatively using cytology specimens, thus reducing the reliance on post-operative histopathology [40]. TERT promoter and TP53 mutations occur at later stages in the development of FTC and are associated with de-differentiation and aggressiveness, suggesting high recurrence, metastasis, and mortality [41]. PAX8/PPARγ rearrangements are detected in 10–40% of FTC, suggesting low aggressiveness and a better prognosis [42]. Combined multigene testing can improve the diagnostic sensitivity of FTC and reduce misdiagnoses. Although traditional diagnostic methods for FTC have some limitations, the use of liquid biopsy and gene expression classifiers has improved the pre-operative diagnosis of FTC. Liquid biopsy, an emerging non-invasive detection technology, provides new parameters for the diagnosis of FTC through the detection of biomarkers, such as circulating tumor cells, ctDNA, tumor exosomes, and metabolic markers in body fluids [43, 44]. ctDNA is an important biomarker in liquid biopsies that reflects the genetic characteristics the tumor. ctDNA, which is specifically mutated in the tumor, is detected in the blood of patients with FTC and it is also a key biomarker of tumor genes. Detection of ctDNA in the blood of patients with FTC with specific mutations, such as RAS, assists in making an early diagnosis, monitoring of treatment response, and prediction of recurrence [45]. Tumor metabolic markers are a group of biomarkers that reflect the abnormal metabolism of tumor cells and have gradually gained attention in the differential diagnosis of thyroid tumors. For example, the serum fatty acid and glycerophospholipid levels in patients with FTC are significantly different from those in FA, which is associated with altered expression of genes related to fatty acid metabolism and may indicate tumor progression [46]. The presence of circulating tumor cells can be detected after they are shed from the primary site into body fluids, and tumor exosomes can be released into body fluids containing tumor-specific molecules, both of which can provide detectable tumor-related information for early diagnosis of FTC [47, 48]. However, there are still challenges in the application of liquid biopsy in the diagnosis of FTC. The small quantity and poor quality of extracted ctDNA affect the accuracy of the test, and the extremely low quantity of ctDNA in patients at an early-stage leads to insufficient sensitivity of the test and difficulty in detecting low-frequency mutations [49]. More efficient and sensitive DNA extraction and analysis methods must be developed to improve reliability. Gene expression classifiers can distinguish between benign and malignant tumors at the molecular level by analyzing RNA expression profiles, which can be used in scenarios where traditional diagnostic methods are equivocal and there is difficultly in clarifying the type of tumor. For example, the Afirma Gene Expression Classifier that focuses on the rapid screening of benign lesions, and the ThyroSeq v3 Gene Classifier that includes detection of DNA mutations and is more conducive for the identification of invasive subtypes, have shown high sensitivity [50, 51]. Gene expression classifiers have great potential for diagnosing FTC; however, they have limitations, such as sample processing, marker uncertainty, and model performance, which are required to be resolved through optimizing of the process, screening for reliable markers, and improving model performance to improve accuracy and reliability. The treatment of patients with FTC currently advocates multidisciplinary comprehensive treatment based on surgery. Surgery is the treatment of choice for patients with resectable thyroid cancer and recurrent disease, and RAI can also be used as an adjunct post-surgery, if RAI-sensitive lesions remain or are suspected to remain during surgery [27]. Treatment of distant metastatic lesions of FTC requires an individualized strategy based on the sensitivity of the lesion to RAI, the site of metastasis, and the molecular characteristics, including surgery, RAI therapy, targeted therapy, and topical therapy [9, 27]. RAI can be used to destroy residual thyroid tissue and for the presumption or treatment of occult microscopic lesions or distant metastases [52]. TKIs play an important role in RAI-refractory patients and in patients with progressive metastatic FTC [53]. TKIs approved for the treatment of FTC include lenvatinib, sorafenib, and cabozantinib [54–56], and although anilotinib has not yet been approved, it has potential [57]. Lenvatinib and sorafenib are the cornerstones of treatment for patients with RAI-refractory FTC, significantly prolonging patient survival. However, TKIs have limitations, including limited efficacy with large inter-individual differences, prominent resistance, high incidence of adverse effects, and the absence of the precise efficacy of predictive markers. These difficulties can be gradually overcome through the development of novel TKIs and combination regimens, in-depth studies of drug resistance mechanisms, the development of countermeasure strategies to minimize adverse reactions, and the search for and validation of accurate efficacy of predictive markers. Conclusion and prospect The prognosis of patients with FTC can be improved through standardized diagnosis and treatment, but pre-operative and intra-operative identification of FA or NIFTP is still a key challenge. Imaging and FNA have a limited role in the pre-operative diagnosis, but FNA can suggest the possibility of follicular tumors. This may assist in further differentiating between FTC, FA, and NIFTP. Highly sensitive detection of specific biomolecular markers, such as TERT mutations, and liquid biopsies show promise in the differential diagnosis of FTC, FA, and NIFTP, which can assist in determining whether a nodule is benign or malignant and guide further investigations and treatment decisions. Future studies should further optimize diagnostic techniques, develop new biomarkers, and improve diagnostic efficacy through comprehensive evaluations based on histopathology, imaging, and molecular markers. Emerging technologies, such as artificial intelligence and joint multi-omics analyses are expected to provide new solutions for the diagnosis of FTC. Basic studies into the treatment of FTC should be strengthened to provide an in-depth exploration of the pathogenesis of the disease, and to establish more precise and personalized treatment protocols and standards to enhance treatment efficacy and improve patient prognosis. This case report has several inherent limitations that should be acknowledged. First, as a single-case study, the findings lack generalizability to the broader population of follicular thyroid neoplasms, and the long-term misdiagnosis and delayed metastasis observed may represent an uncommon clinical scenario. Second, the 11-year interval between initial surgery and distant metastasis limits the ability to establish a direct temporal or causal relationship between the initial histological misdiagnosis, potential biological characteristics of the tumor, and metastatic progression, due to the lack of continuous follow-up data and molecular profiling during this period. Additionally, the retrospective nature of the study precluded standardized collection of comprehensive clinical, radiological, and molecular data (e.g., long-term dynamic changes in thyroid function, serial imaging evaluations, or sequential genetic profiling) that could further clarify the tumor’s natural history. Finally, the absence of comparative analysis with similar cases or systematic literature on long-term outcomes of misdiagnosed follicular thyroid carcinoma restricts the depth of discussion on risk factors for delayed metastasis and optimal management strategies. These limitations highlight the need for larger-scale retrospective cohorts or multi-center studies to validate the clinical implications of our findings and refine diagnostic and follow-up protocols for cytologically or histologically indeterminate thyroid follicular lesions.